Product Code: GVR-4-68039-924-2
Coronary Heart Disease Diagnostic Imaging Devices Market Growth & Trends:
The global coronary heart disease diagnostic imaging device market size is expected to reach USD 2.96 billion by 2030, registering a CAGR of 6.6% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increase in coronary diseases and deaths associated with it calls for better and early diagnosis of the condition. Precise scan interpretation and technologically advanced equipment are the factors influencing the market growth. Various imaging modalities are useful in identifying unique aspects of coronary screening. For instance, intravascular ultrasound, X-ray angiography, and computed tomography angiography (CTCA) provide a direct evaluation and quantification of alterations in the coronary arteries. However, non-invasive techniques like single-photon computed tomography (SPECT) and positron emission tomography (PET) provide indirect information on CHD by estimating the myocardial perfusion and metabolism abnormalities that are consequent of coronary artery disease.
Technological advancement in this field had led to the development of sharp camera units consisting of gamma systems, that use semiconductor detectors of cadmium zinc telluride (CZT). This led to faster acquisition of images, reduced capture time, high image quality, and lower radiation dose (1mSv for a single injection), as compared to conventional myocardial perfusion imaging by SPECT. Further, improvements around Computed Tomography, to develop non-invasive techniques have also shown great future growth in this segment. However, economic barriers, subject literacy, and lack of medical staff hold back the implementation of such advanced techniques in real practice.
The coronary heart disease diagnostic imaging devices market saw a sharp decline in 2020, due to the outbreak of the COVID-19 pandemic. Fear of virus spread, the shift in focus on diagnosing and treating COVID-19 affected patients, reduced admission rates at hospitals for other diseases, and reduced medical staff, led to the reduction in the diagnosis of CVD. Economic setback observed by end-users also influenced the adoption of advanced techniques to effectively diagnoses coronary alterations. Further, the shutting down of manufacturing units, due to national lockdowns, halt in logistics, and reduction in salesforce also impacted the market negatively.
Coronary Heart Disease Diagnostic Imaging Devices Market Report Highlights:
- Nuclear medicine dominated the modality segment due to the ease of image interpretation and accuracy in detection.
- Computed tomography is anticipated to experience at the fastest CAGR o vefr the forecast period, due to its advantages of early detection of even the most intricate alterations which otherwise is impossible to det4ect in the traditional SPECT technology.
- Asia Pacific is anticipated to be growing at a significant CAGR over the forecast period owing to the increase in R&D activities and numerous resellers.
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Modality
- 1.2.2. Regional scope
- 1.2.3. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
- 1.4.5.1. Data for primary interviews in North America
- 1.4.5.2. Data for primary interviews in Europe
- 1.4.5.3. Data for primary interviews in Asia Pacific
- 1.4.5.4. Data for primary interviews in Latin America
- 1.4.5.5. Data for Primary interviews in MEA
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Modality outlook
- 2.2.2. Regional outlook
- 2.3. Competitive Insights
Chapter 3. Coronary Heart Disease Diagnostic Imaging Device Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. Increasing Prevalence Of Coronary Artery Diseases
- 3.2.1.2. Rising Adoption Of Early Diagnostic Techniques
- 3.2.2. Market restraint analysis
- 3.2.2.1. Lack of Skilled Radiologists
- 3.3. Coronary Heart Disease Diagnostic Imaging Device Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Technological landscape
- 3.3.2.3. Economic landscape
- 3.3.3. Pipeline Analysis
Chapter 4. Coronary Heart Disease Diagnostic Imaging Device Market: Modality Estimates & Trend Analysis
- 4.1. Global Coronary Heart Disease Diagnostic Imaging Device Market: Modality Dashboard
- 4.2. Global Coronary Heart Disease Diagnostic Imaging Device Market: Modality Movement Analysis
- 4.3. Global Coronary Heart Disease Diagnostic Imaging Device Market by Modality, Revenue
- 4.4. Computed Tomography
- 4.4.1. Computed Tomography market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.5. X rays
- 4.5.1. X rays market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.6. Ultrasound
- 4.6.1. Ultrasound market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.7. Magnetic Resonance Imaging
- 4.7.1. Magnetic Resonance Imaging market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.8. Nuclear Medicine
- 4.8.1. Nuclear Medicine market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Coronary Heart Disease Diagnostic Imaging Device Market: Regional Estimates & Trend Analysis by Modality
- 5.1. Regional Dashboard
- 5.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030
- 5.3. North America
- 5.3.1. U.S.
- 5.3.1.1. Key country dynamics
- 5.3.1.2. Regulatory framework/ reimbursement structure
- 5.3.1.3. Competitive scenario
- 5.3.1.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.3.2. Canada
- 5.3.2.1. Key country dynamics
- 5.3.2.2. Regulatory framework/ reimbursement structure
- 5.3.2.3. Competitive scenario
- 5.3.2.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.3.3. Mexico
- 5.3.3.1. Key country dynamics
- 5.3.3.2. Regulatory framework/ reimbursement structure
- 5.3.3.3. Competitive scenario
- 5.3.3.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4. Europe
- 5.4.1. UK
- 5.4.1.1. Key country dynamics
- 5.4.1.2. Regulatory framework/ reimbursement structure
- 5.4.1.3. Competitive scenario
- 5.4.1.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4.2. Germany
- 5.4.2.1. Key country dynamics
- 5.4.2.2. Regulatory framework/ reimbursement structure
- 5.4.2.3. Competitive scenario
- 5.4.2.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4.3. France
- 5.4.3.1. Key country dynamics
- 5.4.3.2. Regulatory framework/ reimbursement structure
- 5.4.3.3. Competitive scenario
- 5.4.3.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4.4. Italy
- 5.4.4.1. Key country dynamics
- 5.4.4.2. Regulatory framework/ reimbursement structure
- 5.4.4.3. Competitive scenario
- 5.4.4.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4.5. Spain
- 5.4.5.1. Key country dynamics
- 5.4.5.2. Regulatory framework/ reimbursement structure
- 5.4.5.3. Competitive scenario
- 5.4.5.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4.6. Norway
- 5.4.6.1. Key country dynamics
- 5.4.6.2. Regulatory framework/ reimbursement structure
- 5.4.6.3. Competitive scenario
- 5.4.6.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4.7. Sweden
- 5.4.7.1. Key country dynamics
- 5.4.7.2. Regulatory framework/ reimbursement structure
- 5.4.7.3. Competitive scenario
- 5.4.7.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4.8. Denmark
- 5.4.8.1. Key country dynamics
- 5.4.8.2. Regulatory framework/ reimbursement structure
- 5.4.8.3. Competitive scenario
- 5.4.8.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.5. Asia Pacific
- 5.5.1. Japan
- 5.5.1.1. Key country dynamics
- 5.5.1.2. Regulatory framework/ reimbursement structure
- 5.5.1.3. Competitive scenario
- 5.5.1.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.5.2. China
- 5.5.2.1. Key country dynamics
- 5.5.2.2. Regulatory framework/ reimbursement structure
- 5.5.2.3. Competitive scenario
- 5.5.2.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.5.3. India
- 5.5.3.1. Key country dynamics
- 5.5.3.2. Regulatory framework/ reimbursement structure
- 5.5.3.3. Competitive scenario
- 5.5.3.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.5.4. Australia
- 5.5.4.1. Key country dynamics
- 5.5.4.2. Regulatory framework/ reimbursement structure
- 5.5.4.3. Competitive scenario
- 5.5.4.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.5.5. South Korea
- 5.5.5.1. Key country dynamics
- 5.5.5.2. Regulatory framework/ reimbursement structure
- 5.5.5.3. Competitive scenario
- 5.5.5.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.5.6. Thailand
- 5.5.6.1. Key country dynamics
- 5.5.6.2. Regulatory framework/ reimbursement structure
- 5.5.6.3. Competitive scenario
- 5.5.6.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.6. Latin America
- 5.6.1. Brazil
- 5.6.1.1. Key country dynamics
- 5.6.1.2. Regulatory framework/ reimbursement structure
- 5.6.1.3. Competitive scenario
- 5.6.1.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.6.2. Argentina
- 5.6.2.1. Key country dynamics
- 5.6.2.2. Regulatory framework/ reimbursement structure
- 5.6.2.3. Competitive scenario
- 5.6.2.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.7. MEA
- 5.7.1. South Africa
- 5.7.1.1. Key country dynamics
- 5.7.1.2. Regulatory framework/ reimbursement structure
- 5.7.1.3. Competitive scenario
- 5.7.1.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.7.2. Saudi Arabia
- 5.7.2.1. Key country dynamics
- 5.7.2.2. Regulatory framework/ reimbursement structure
- 5.7.2.3. Competitive scenario
- 5.7.2.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.7.3. UAE
- 5.7.3.1. Key country dynamics
- 5.7.3.2. Regulatory framework/ reimbursement structure
- 5.7.3.3. Competitive scenario
- 5.7.3.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.7.4. Kuwait
- 5.7.4.1. Key country dynamics
- 5.7.4.2. Regulatory framework/ reimbursement structure
- 5.7.4.3. Competitive scenario
- 5.7.4.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Competitive Landscape
- 6.1. Company/Competition Categorization
- 6.2. Vendor Landscape
- 6.2.1. List of key distributors and channel partners
- 6.2.2. Key customers
- 6.2.3. Key company market share analysis, 2024
- 6.2.4. GE Healthcare
- 6.2.4.1. Company overview
- 6.2.4.2. Financial performance
- 6.2.4.3. Product benchmarking
- 6.2.4.4. Strategic initiatives
- 6.2.5. Koninklijke Phillips N.V.
- 6.2.5.1. Company overview
- 6.2.5.2. Financial performance
- 6.2.5.3. Product benchmarking
- 6.2.5.4. Strategic initiatives
- 6.2.6. Canon
- 6.2.6.1. Company overview
- 6.2.6.2. Financial performance
- 6.2.6.3. Product benchmarking
- 6.2.6.4. Strategic initiatives
- 6.2.7. Siemens Healthineers AG
- 6.2.7.1. Company overview
- 6.2.7.2. Financial performance
- 6.2.7.3. Product benchmarking
- 6.2.7.4. Strategic initiatives
- 6.2.8. Ziehm Imaging GmbH
- 6.2.8.1. Company overview
- 6.2.8.2. Financial performance
- 6.2.8.3. Product benchmarking
- 6.2.8.4. Strategic initiatives
- 6.2.9. Esaote SPA
- 6.2.9.1. Company overview
- 6.2.9.2. Financial performance
- 6.2.9.3. Product benchmarking
- 6.2.9.4. Strategic initiatives
- 6.2.10. Hitachi Medical Corporation
- 6.2.10.1. Company overview
- 6.2.10.2. Financial performance
- 6.2.10.3. Product benchmarking
- 6.2.10.4. Strategic initiatives
- 6.2.11. SAMSUNG
- 6.2.11.1. Company overview
- 6.2.11.2. Financial performance
- 6.2.11.3. Product benchmarking
- 6.2.11.4. Strategic initiatives
- 6.2.12. FUJIFILM Holdings Corporation
- 6.2.12.1. Company overview
- 6.2.12.2. Financial performance
- 6.2.12.3. Product benchmarking
- 6.2.12.4. Strategic initiatives